Роль полиморфного варианта генов фолатного цикла в клинике розацеа
Keywords:
розацеа, генетические маркеры, генетический анализ подтипов, сочетание подтипов
Abstract
Патогенез розацеа на сегодняшний день остается до конца не изученным. Остаетсяоткрытым и обсуждаемым вопрос, как можно объяснить степень тяжести и степень выраженностиразличных клинических симптомов розацеа у конкретного пациента. Какие механизмы регулируют прогрессирование процесса, приводящее к сочетанию подтипов и тяжелому течению у одних пациентов и проявление заболевания в пределах одногоподтипа без тенденции к усугублению у других. Цель исследования: изучить генетические маркеры1298 A>C генаMTHFR (rs1801131),677C>T гена MTHFR (rs1801133), 2756 A>Gгена MTR(rs1805087) и 66A>Gгена MTRR (rs1801394)при эритематозно-телеангиэктатическом и папуло-пустулезно подтипах розацеа. Материалы и методы исследования. В исследовании участвовали 27 человек, которые в зависимости от клиническойкартины розацеа были распределены на три группы, сравнение результатов проводилось с 20 здоровыми добровольцами. Результаты и их обсуждение
Downloads
Download data is not yet available.
References
1. Abram K., Silm H., Maaroos H-I. Risk factors associated with rosacea // J. EurAcad Dermatol Venereol.2010. Vol. 24. P. 565–571.
2. Abrams K., Silm H., Oona M. Prevalence of rosacea in an Estonian working population using a standard classification // J. Acta DermVenereol. 2010.
Vol. 90. P. 269–273.
3. Al-Dabagh A., Davis S.A., McMichael A.J. Rosaceain skin of color: not a rare diagnosis // J. DermatolOnline. 2014.
4. Aldrich N., Gerstenblith M., Fu P., Tuttle M.S.,Varma P., Gotow E., Cooper K.D., Mann M.,Popkin D.L. Genetic vs. environmental factors thatcorrelate with rosacea: A cohort-based survey of twins// J. JAMA Dermatol. 2015. Vol. 151. P. 1213–1219.
5. Bae YI, Yun SJ, Lee JB. Clinical evaluation of 168Korean patients with rosacea: the sun exposure correlates with the erythematotelangiectatic subtype. J.Ann Dermatol. 2009;21:243-9.
6. Berg M., Liden S. An epidemiological study of rosacea // J Acta DermVenereol. 1989. Vol. 69. P. 419–423.
7. Buhl T, Sulk M, Nowak P. Molecular and morphological characterization of inflammatory infiltrate inrosacea reveals activation of Th1/Th17 pathways. J
.Invest Dermatol. 2015;135:2198-208.
8. Chang A.L., Raber I., Xu J., Li R., Spitale R., ChenJ., Kiefer A.K., Tian C., Eriksson N.K., Hinds D.A. Assessment of the genetic basis of rosacea by genomewide association study // J. Investig. Dermatol. 2015.Vol. 135. P. 1548–1555.
9. Del Rosso JQ, Thiboutot D, Gallo R. Consensusrecommendations from the American Acne andRosacea Society on the management of rosacea, part 1: astatus report on the disease state, general measures,and adjunctive skin care. J. Cutis. 2013;92(5):234-40.
10. Del Rosso J.Q., Gallo R.L., Tanghetti E. An evaluation of potential correlations between pathophysiologic mechanisms, clinical manifestations, and
management of rosacea // J. Cutis. 2013.Vol. 91(suppl3). P. 1–8.
11. Dlova N, Mosam A. Rosacea in black South Africans with skin phototypes V and VI. J.Clin Exp Dermatol. 2017;42:670-3.
12. Gomaa AHA, Yaar M, Eyada MMK, Bhawan J. Lymphangiogenesis and angiogenesis in non-phymatousrosacea.// J of CutanPathol. 2007;34(10):748–753. doi: 10.1111/j.1600-0560.2006. 00695.
13. Holmes A.D., Steinhoff M. Integrative concepts ofrosacea pathophysiology, clinical presentation andnew therapeutics // J. Exp Dermatol. 2017. Vol. 26.P. 659–667.
14. F Dall’Oglio, C.Fusto, G. Micali Intrafamilial Transmission of Rosacea Spanning Six Generations: A Retrospective Observational Study.//J Clin AesthetDermatol-2022 Feb;15(2):35-39
15. Karpouzis A, Avgeridis P, Tripsianis G, Gatzidou E. Assessment of tachykinin receptor 3′ gene polymorphism rs3733631 in rosacea. Int. Sch. Res. Not.
2015;2015:469402.
16. McAleer MA, Fitzpatrick P, Powell FC. The prevalence and pathogenesis of rosacea; 2008.
17. Palleschi GM, Torchia D. Rosacea in a monozygotic twin. Australas. J. Dermatol. 2007;:48:132-3.
18. Schwab V.D., Sulk M., Seeliger S. Neurovascular
and neuroimmune aspects in the pathophysiology ofrosacea // J. Invest Dermatol Symp Proc. 2011.Vol. 15. P. 53–62.
19. 19.Smith JR, Lanier VB, Braziel RM, Falkenhagen KM, White C, Rosenbaum JT. Expression of vascular endothelial growth factor and its receptors in rosacea. //Br J Ophthalmol. 2007;91(2):226–229. doi: 10.1136/bjo.2006.101121.
20. Steinhoff M, Buddenkotte J, Aubert J, Sulk M,Novak P, Schwab VD. Clinical, cellular, and molecularaspects in the pathophysiology of rosacea. J. InvestigDermatol Symp Proc. 2011;15:2-11.
21. Tan J., Almeida L., Bewley A. Updating the diagnosis,classification and assessment of rosacea: recommendations from the global ROSaceaCOnsensus (ROSCO)panel // J Dermatol. 2017. Vol. 176. P. 431–438.
22. Tan J, Blume-Peytavi U, Ortonne JP. An observational cross-sectional survey of rosacea: clinical associations and progression between subtypes. Br J Dermatol. 2013;169:555-62.
23. Tan J., Sch€ofer H., Araviiskaia E. Prevalence ofrosacea in the general population of Germany andRussia the RISE study // J EurAcad Dermatol Venereol. 2016. Vol. 30. P. 428–434.
24. Trivedi NR, Gilliland KL, Zhao W. Gene arrayexpression profiling in acne lesions reveals markedupregulation of genes involved in inflammation andmatrix remodeling. J. Invest Dermatol.2006;126:1071-9.
25. Weinstock L.B., Steinhoff M. Rosacea and smallintestinal bacterial overgrowth: prevalence and response to rifaximin // J. Am Acad Dermatol. 2013.Vol. 68. P. 875–876.
26. Wilkin J, Dahl M, Detmar M. Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J. Am Acad Dermatol. 2002;46:584-7.
27. Wladis E.J., Iglesias B.V., Adam A.P. Molecularbiologic assessment of cutaneous specimens of ocularrosacea // J. OphthalPlastReconstr Surg. 2012.Vol. 28. P. 246–250.
28. Yamasaki K., Di Nardo A., Bardan A. Increasedserine protease activity and cathelicidin promotesskin inflammation in rosacea // J. Nat Med. 2007.
Vol. 13. P. 975–980.
2. Abrams K., Silm H., Oona M. Prevalence of rosacea in an Estonian working population using a standard classification // J. Acta DermVenereol. 2010.
Vol. 90. P. 269–273.
3. Al-Dabagh A., Davis S.A., McMichael A.J. Rosaceain skin of color: not a rare diagnosis // J. DermatolOnline. 2014.
4. Aldrich N., Gerstenblith M., Fu P., Tuttle M.S.,Varma P., Gotow E., Cooper K.D., Mann M.,Popkin D.L. Genetic vs. environmental factors thatcorrelate with rosacea: A cohort-based survey of twins// J. JAMA Dermatol. 2015. Vol. 151. P. 1213–1219.
5. Bae YI, Yun SJ, Lee JB. Clinical evaluation of 168Korean patients with rosacea: the sun exposure correlates with the erythematotelangiectatic subtype. J.Ann Dermatol. 2009;21:243-9.
6. Berg M., Liden S. An epidemiological study of rosacea // J Acta DermVenereol. 1989. Vol. 69. P. 419–423.
7. Buhl T, Sulk M, Nowak P. Molecular and morphological characterization of inflammatory infiltrate inrosacea reveals activation of Th1/Th17 pathways. J
.Invest Dermatol. 2015;135:2198-208.
8. Chang A.L., Raber I., Xu J., Li R., Spitale R., ChenJ., Kiefer A.K., Tian C., Eriksson N.K., Hinds D.A. Assessment of the genetic basis of rosacea by genomewide association study // J. Investig. Dermatol. 2015.Vol. 135. P. 1548–1555.
9. Del Rosso JQ, Thiboutot D, Gallo R. Consensusrecommendations from the American Acne andRosacea Society on the management of rosacea, part 1: astatus report on the disease state, general measures,and adjunctive skin care. J. Cutis. 2013;92(5):234-40.
10. Del Rosso J.Q., Gallo R.L., Tanghetti E. An evaluation of potential correlations between pathophysiologic mechanisms, clinical manifestations, and
management of rosacea // J. Cutis. 2013.Vol. 91(suppl3). P. 1–8.
11. Dlova N, Mosam A. Rosacea in black South Africans with skin phototypes V and VI. J.Clin Exp Dermatol. 2017;42:670-3.
12. Gomaa AHA, Yaar M, Eyada MMK, Bhawan J. Lymphangiogenesis and angiogenesis in non-phymatousrosacea.// J of CutanPathol. 2007;34(10):748–753. doi: 10.1111/j.1600-0560.2006. 00695.
13. Holmes A.D., Steinhoff M. Integrative concepts ofrosacea pathophysiology, clinical presentation andnew therapeutics // J. Exp Dermatol. 2017. Vol. 26.P. 659–667.
14. F Dall’Oglio, C.Fusto, G. Micali Intrafamilial Transmission of Rosacea Spanning Six Generations: A Retrospective Observational Study.//J Clin AesthetDermatol-2022 Feb;15(2):35-39
15. Karpouzis A, Avgeridis P, Tripsianis G, Gatzidou E. Assessment of tachykinin receptor 3′ gene polymorphism rs3733631 in rosacea. Int. Sch. Res. Not.
2015;2015:469402.
16. McAleer MA, Fitzpatrick P, Powell FC. The prevalence and pathogenesis of rosacea; 2008.
17. Palleschi GM, Torchia D. Rosacea in a monozygotic twin. Australas. J. Dermatol. 2007;:48:132-3.
18. Schwab V.D., Sulk M., Seeliger S. Neurovascular
and neuroimmune aspects in the pathophysiology ofrosacea // J. Invest Dermatol Symp Proc. 2011.Vol. 15. P. 53–62.
19. 19.Smith JR, Lanier VB, Braziel RM, Falkenhagen KM, White C, Rosenbaum JT. Expression of vascular endothelial growth factor and its receptors in rosacea. //Br J Ophthalmol. 2007;91(2):226–229. doi: 10.1136/bjo.2006.101121.
20. Steinhoff M, Buddenkotte J, Aubert J, Sulk M,Novak P, Schwab VD. Clinical, cellular, and molecularaspects in the pathophysiology of rosacea. J. InvestigDermatol Symp Proc. 2011;15:2-11.
21. Tan J., Almeida L., Bewley A. Updating the diagnosis,classification and assessment of rosacea: recommendations from the global ROSaceaCOnsensus (ROSCO)panel // J Dermatol. 2017. Vol. 176. P. 431–438.
22. Tan J, Blume-Peytavi U, Ortonne JP. An observational cross-sectional survey of rosacea: clinical associations and progression between subtypes. Br J Dermatol. 2013;169:555-62.
23. Tan J., Sch€ofer H., Araviiskaia E. Prevalence ofrosacea in the general population of Germany andRussia the RISE study // J EurAcad Dermatol Venereol. 2016. Vol. 30. P. 428–434.
24. Trivedi NR, Gilliland KL, Zhao W. Gene arrayexpression profiling in acne lesions reveals markedupregulation of genes involved in inflammation andmatrix remodeling. J. Invest Dermatol.2006;126:1071-9.
25. Weinstock L.B., Steinhoff M. Rosacea and smallintestinal bacterial overgrowth: prevalence and response to rifaximin // J. Am Acad Dermatol. 2013.Vol. 68. P. 875–876.
26. Wilkin J, Dahl M, Detmar M. Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J. Am Acad Dermatol. 2002;46:584-7.
27. Wladis E.J., Iglesias B.V., Adam A.P. Molecularbiologic assessment of cutaneous specimens of ocularrosacea // J. OphthalPlastReconstr Surg. 2012.Vol. 28. P. 246–250.
28. Yamasaki K., Di Nardo A., Bardan A. Increasedserine protease activity and cathelicidin promotesskin inflammation in rosacea // J. Nat Med. 2007.
Vol. 13. P. 975–980.
Published
2023-10-31
How to Cite
Агзамходжаева С. С., Азизов Б. С., Нишанова М. А., & Нурматова И. Б. (2023). Роль полиморфного варианта генов фолатного цикла в клинике розацеа. Central Asian Journal of Theoretical and Applied Science, 4(10), 231-243. Retrieved from https://cajotas.centralasianstudies.org/index.php/CAJOTAS/article/view/1326
Section
Articles
